Cover Image

Long-term safety and effectiveness of Rezafungin treatment in candidemia and invasive candidiasis: results from an early access program in Italy and Germany

Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the progr...

Full description

Saved in:
Bibliographic Details
Main Authors: Trapani, Filippo (Author) , Viceconte, Giulio (Author) , Morena, Valentina (Author) , Tiseo, Giusy (Author) , Mori, Giovanni (Author) , Kölking, Britta (Author) , Khatamzas, Elham (Author)
Format: Article (Journal)
Language:English
Published: March 2025
In: Open Forum Infectious Diseases
Year: 2025, Volume: 12, Issue: 3, Pages: 1-6
ISSN:2328-8957
DOI:10.1093/ofid/ofaf034
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1093/ofid/ofaf034
Get full text
Author Notes:Filippo Trapani, Giulio Viceconte, Valentina Morena, Giusy Tiseo, Giovanni Mori, Britta Kölking, and Elham Khatamzas
Description
Summary:Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.
Item Description:Veröffentlicht: 19. März 2025
Gesehen am 19.08.2025
Physical Description:Online Resource
ISSN:2328-8957
DOI:10.1093/ofid/ofaf034

Similar Items